Binocular and Monocular Distance-Corrected Visual Performance and Defocus Characteristics of Clareon Truplus Intraocular Lens (IOL) (BMVDI)

Inclusion Criteria:

• Able and willing to understand and sign informed consent.
• Able and willing to complete all required study visits.
• Diagnosed with age-related cataracts in both eyes (OU)
• Bilateral age-related cataract scheduled for phacoemulsification in both eyes by a single surgeon.
• Surgeon predicts postoperative best corrected distance visual acuity (BCDVA) of ≥ 20/25 or better with Manifest Refractive Spherical Equivalent (MRSE) ±0.50 D of plano and in each eye post-operatively.
• Clear intraocular media aside from cataract.
• Will receive TruPlus bilaterally
• Postoperative residual astigmatism ≤ 0.75 D in both eyes.
• Refractive target: Emmetropia OU
• Patient groups agreeing to either Femtosecond Laser Assisted Cataract Surgery (FLACS) or Standard phaco

Exclusion Criteria:

• Ocular comorbidities affecting visual outcomes, including but not limited to:
• Macular disease (e.g., Age-Related Macular Degeneration [AMD], Diabetic Macular Edema [DME], Epiretinal Membrane [ERM]).
• Active ocular inflammation.
• Any investigator-determined condition likely to confound postoperative visual performance.
• Strabismus with or without amblyopia in either eye.
• Prior anterior or posterior segment surgery, including corneal refractive procedures.
• History of retinal detachment.
• Degenerative retinal or visual disorders deemed clinically significant by the investigator.
• Diagnosed glaucoma (of any stage, if deemed vision-impacting by investigator).
• Systemic conditions that could affect healing or study outcomes (e.g., immunocompromised, connective tissue disease, clinically significant atopy, diabetes).